Press release
Rare NRG1 Fusion Market is projected to reach USD 346 million by 2034
Rare NRG1 Fusion
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70909
NRG1 fusions are rare but actionable oncogenic drivers found in a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, breast cancer, cholangiocarcinoma, and others. These fusions activate HER3/HER2 signaling, leading to uncontrolled tumor growth-making HER3-targeted inhibition a major therapeutic frontier.
Key Market Highlights
• 2024 Market Size: USD 128 million
• 2034 Forecast: USD 346 million
• CAGR (2025-2034): 10.4%
• Largest Segment: HER3-targeted therapies
• Fastest-Growing Segment: NGS companion diagnostics & precision oncology platforms
Epidemiology & Clinical Insights
1. Prevalence
NRG1 fusions occur in approximately:
• 0.3% of solid tumors,
• 1-2% of KRAS-wild-type pancreatic cancers,
• 0.2-0.5% of NSCLC, particularly in never-smokers.
Despite being rare, they represent a high-value precision oncology segment because targeted therapies produce meaningful clinical responses.
2. Tumor Types Affected
NRG1 fusions appear across multiple cancers:
• Non-small cell lung cancer (NSCLC)
• Pancreatic adenocarcinoma
• Breast cancer
• Ovarian cancer
• Prostate cancer
• Cholangiocarcinoma
• Colorectal cancer
3. Molecular Characteristics
NRG1 fusions:
• Activate HER3 (ERBB3) receptors
• Form heterodimers with HER2 or EGFR
• Drive tumor proliferation and survival
Advanced genomic profiling (RNA sequencing, hybrid capture) is now essential for detection.
Market Growth Drivers
1. Rising Adoption of NGS & Comprehensive Genomic Profiling
More cancer centers integrate fusion testing as part of standard oncology workflows.
2. Strong Pipeline of HER3-Targeted Therapies
Companies are developing monoclonal antibodies, bispecific antibodies, and pan-ERBB inhibitors.
3. Increasing Recognition of NRG1 as an Actionable Driver
Growing awareness among oncologists improves diagnosis and therapeutic targeting.
4. Basket & Umbrella Clinical Trials
Tumor-agnostic trial designs accelerate development and approval pathways.
5. Expansion of Precision Oncology Reimbursement
Governments and insurers increasingly support NGS testing.
Market Restraints
• Extremely low prevalence limits large trials
• High cost of targeted therapies
• Inconsistent access to advanced sequencing in emerging regions
• Heterogeneity in fusion partners complicates diagnostic workflows
Market Opportunities
1. HER3 Inhibitors & Bispecific Antibodies
Novel agents designed specifically for NRG1-fusion-positive tumors.
2. Tumor-Agnostic Regulatory Approvals
NRG1 fusion therapies may receive approvals similar to NTRK and RET inhibitors.
3. AI-Driven Biomarker Detection
Machine-learning models enhance identification of rare fusions.
4. Liquid Biopsy Expansion
ctDNA-based testing supports early diagnosis and therapy monitoring.
5. Personalized Combination Therapy
HER3 inhibitors combined with:
• HER2 inhibitors
• MEK inhibitors
• Immune checkpoint inhibitors
Segmentation Overview
By Tumor Type
• NSCLC
• Pancreatic cancer
• Breast cancer
• Cholangiocarcinoma
• Colorectal cancer
• Others
By Therapy Type
• HER3-targeted monoclonal antibodies
• Bispecific HER2/HER3 antibodies
• Pan-ERBB inhibitors
• Small molecule kinase inhibitors
• Combination therapies
By Diagnostic Method
• NGS panels
• RNA sequencing
• Liquid biopsy (ctDNA)
• Immunohistochemistry (limited utility)
By End User
• Hospitals & cancer centers
• Precision oncology laboratories
• Research institutes
• Pharmaceutical organizations
Explore Full Report here: https://exactitudeconsultancy.com/reports/70909/rare-nrg1-fusion-market
Regional Insights
North America - Largest Market
Strong genomic testing adoption, leading precision oncology centers, and active clinical pipelines.
Europe - Growing Adoption
Germany, UK, France, and Italy implement widespread NGS-based diagnostics and basket trial participation.
Asia Pacific - Fastest Growing
Large cancer population, increasing biomarker testing, and expanding research collaborations.
Latin America - Developing
Gradual expansion of sequencing access and oncology infrastructure.
Middle East & Africa - Emerging
Investment in cancer genomics centers supports long-term growth.
Competitive Landscape
Major companies and research groups developing therapies for NRG1 fusion-positive tumors include:
• Merus - Zenocutuzumab (HER2/HER3 bispecific antibody)
• Boehringer Ingelheim - BI 1701963 (SOS1 inhibitor; synergy potential)
• Fusion Pharmaceuticals - Radiopharmaceutical approaches
• Roche / Genentech - HER3-targeting platforms
• Amgen - Bispecific antibody innovation
• AstraZeneca - Pan-ERBB pathway inhibitors
• BeiGene
Focus areas include HER3-directed antibodies, fusion-specific assays, and tumor-agnostic clinical strategies.
Recent Market Developments
• Strong clinical results from HER3-targeted bispecific antibodies (e.g., zenocutuzumab)
• Expansion of NRG1 fusion testing guidelines
• Inclusion of NRG1 fusion status in major molecular oncology panels
• Growing use of RNA-based assays to improve detection
• Increasing regulatory dialogue on tumor-agnostic approval pathways
Future Outlook (2025-2034)
The Rare NRG1 Fusion Market will accelerate as:
• Precision oncology becomes standard across cancer care
• HER3-targeted therapy shifts from clinical trials to commercial practice
• NGS and liquid biopsy technologies expand globally
• Tumor-agnostic drug approvals reshape the regulatory environment
By 2034, the market is projected to reach USD 346 million, driven by rapid advancements in targeted therapeutics and improved detection of NRG1 fusion-positive tumors.
This report is also available in the following languages : Japanese (まれなNRG1融合), Korean (희귀한 NRG1 퓨전), Chinese (稀有 NRG1 融合), French (Fusion NRG1 rare), German (Seltene NRG1-Fusion), and Italian (Rara fusione NRG1), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/70909
Our More Reports:
TRK Fusion Cancer Market
https://exactitudeconsultancy.com/reports/71588/trk-fusion-cancer-market
Tropomyosin Receptor Kinase Fusion Cancer Market
https://exactitudeconsultancy.com/reports/72681/tropomyosin-receptor-kinase-fusion-cancer-market
On-body Drug Delivery Devices White Spaces Analysis Market
https://exactitudeconsultancy.com/reports/73462/on-body-drug-delivery-devices-white-spaces-analysis-market
Sensor Fusion Market
https://exactitudeconsultancy.com/reports/73908/sensor-fusion-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rare NRG1 Fusion Market is projected to reach USD 346 million by 2034 here
News-ID: 4311399 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for NRG1
NRG1 Fusion-Targeted Therapy Market Set for 82.5% Growth, Poised to Transform Pr …
The global NRG1 fusion-targeted therapy market is entering a dynamic growth phase, with its value projected to expand from USD 133.1 million in 2025 to approximately USD 242.9 million by 2035. This growth reflects an impressive 82.5% increase over the decade, driven by the accelerating adoption of precision oncology and the need for advanced treatment options for rare cancers. With a compound annual growth rate (CAGR) of 6.2%, the market…
Rare NRG1 Fusion Market to Double by 2035, Driven by Immunotherapy and Precision …
The Rare NRG1 Fusion Market is on track for transformative growth, expected to expand from USD 11.0 billion in 2025 to USD 23.2 billion by 2035, according to the latest industry estimates. Registering a compound annual growth rate (CAGR) of 7.7%, the market is being propelled by innovations in molecular diagnostics, breakthroughs in immunotherapy, and growing integration of precision medicine into mainstream oncology care.
Market Overview
Rare NRG1 fusions-found in approximately 0.2%…
Rare NRG1 Fusion Market Outlook, Epidemiology, Emerging Therapies and Forecast 2 …
Neuregulin 1 (NRG1) fusion-positive cancers represent a rare but clinically significant oncogenic driver found across multiple tumor types, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and other solid tumors. Although the prevalence is low-estimated at less than 0.5% of cancers-NRG1 fusions are actionable targets, meaning patients may respond strongly to precision medicines designed to inhibit fusion-driven pathways.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70909
Historically, patients…
Rare NRG1 Fusion Market Size to Exhibit Moderate Growth by 2034, Evaluates Delve …
DelveInsight's "Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Rare NRG1 Fusion Market with DelveInsight's In-Depth Report @ Rare NRG1 Fusion Market Size- https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr…
Rare NRG1 Fusion Therapeutics Market Size in the 7MM was ~USD 37 million in 2023 …
DelveInsight's "Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Rare NRG1 Fusion Market with DelveInsight's In-Depth Report @ Rare NRG1 Fusion Market Size [https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways…
Rare NRG1 Fusion Market Size in the 7MM was ~USD 37 million in 2023, estimated D …
DelveInsight's "Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Key Takeaways from the Rare NRG1 Fusion Market Report
• Among the 7MM, the US accounted for the highest incident cases of…
